Revelation Biosciences, Inc.

Equities

REVB

US76135L5075

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
2.74 USD +12.76% Intraday chart for Revelation Biosciences, Inc. +11.84% -81.76%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Revelation Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Revelation Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini CI
Top Midday Decliners MT
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Thursday on Unchanged Fed Rate, Upcoming Earnings MT
Top Premarket Decliners MT
Top Premarket Gainers MT
Top Premarket Gainers MT
Revelation Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Revelation Biosciences Inc. Announces Data from Recent Preclinical Studies of the Gemini Formulation Demonstrates Its Therapeutic Potential as A Preventative Therapy Across Multiple Indications Including Infection and Acute Kidney Injury CI
Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla to Board of Directors CI
Revelation Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Revelation Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Certain Warrants of Revelation Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 14-MAY-2023. CI
Certain Common Stock of Revelation Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 14-MAY-2023. CI
Revelation Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Revelation Biosciences, Inc. Auditor Raises 'Going Concern' Doubt CI
Revelation Biosciences Inc. Appoints Dr. Julia Bohannon and Dr. Antonio Hernandez to Scientific Advisory Board CI
Roth MKM Adjusts Price Target on Revelation Biosciences to $15 From $5, Maintains Buy Rating MT
Revelation Biosciences Prices $15.6 Million Securities Offering; Shares Drop Fourth Consecutive Day MT
Top Midday Decliners MT
Revelation Biosciences Prices $15.6 Million Securities Offering; Shares Plunge MT
Top Premarket Decliners MT
Revelation Biosciences Inc. Announces Preclinical Biomarker Data Supporting Activity of REVTx-300 CI
Revelation Biosciences, Inc. announced that it has received $0.005 million in funding CI
Chart Revelation Biosciences, Inc.
More charts
Revelation Biosciences, Inc. is a clinical-stage biopharmaceutical company engaged in the development of innate immune system therapeutics and diagnostics. Its therapeutic candidates are based on the active ingredient phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA) that is known to stimulate Toll-like receptor 4 (TLR-4). Its product candidates include REVTx-300, which is being developed as a potential therapy for the prevention and treatment of acute organ injury and chronic organ disease; REVTx-100, which is being developed for the prevention and treatment of infections, including healthcare-associated bacterial infections resulting from surgery, severe burns, and antibiotic resistance; REVTx-200, which is being developed as a potential intranasal therapy that is administered with a traditional commercially available intramuscular (IM) vaccine, and REVTx-99b, which is being developed as a treatment for food allergies.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.74 USD
Average target price
32.12 USD
Spread / Average Target
+1,072.45%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Revelation Biosciences, Inc. - Nasdaq
  4. News Revelation Biosciences, Inc.
  5. Earnings Flash (REVB) REVELATION BIOSCIENCES Reports Q1 Loss $-0.47